Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves

European Journal of Clinical Pharmacology

Volumn 71, Issue 10, 2015, Pages 1229-1236

  Chung, Jee Eun ^a   Chang, Byung Chul ^b   Lee, Kyung Eun ^a,c   Kim, Joo Hee ^a   Gwak, Hye Sun ^a  

^a Ewha Womans University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

NAD(P)H quinone oxidoreductase 1; Single nucleotide polymorphism; VKORC1; Warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; GAMMA GLUTAMYL CARBOXYLASE; GENOMIC DNA; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; TRANSCRIPTION FACTOR GATA 4; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; WARFARIN; CYP2C9 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; DIPEPTIDASE; GAMMA-GLUTAMYL DIPEPTIDASE; GATA4 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); VKORC1 PROTEIN, HUMAN;

ADULT; ARTICLE; ATRIAL FIBRILLATION; DRUG PROTEIN BINDING; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; MECHANICAL HEART VALVE; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; AGE; AGED; BODY MASS; GENETICS; HEART VALVE PROSTHESIS; MIDDLE AGED; SEX DIFFERENCE; SOUTH KOREA;

AGE FACTORS; AGED; BODY MASS INDEX; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 ENZYME SYSTEM; DIPEPTIDASES; FEMALE; GATA4 TRANSCRIPTION FACTOR; GENE FREQUENCY; GENOTYPE; HEART VALVE PROSTHESIS; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, SINGLE NUCLEOTIDE; REPUBLIC OF KOREA; SEX FACTORS; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84941317229     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1915-y     Document Type: Article

References (26)

1. Tie JK, Jin DY, Straight DL, Stafford DW (2011) Functional study of the vitamin K cycle in mammalian cells. Blood 117(10):2967-2974. doi: 10.1182/blood-2010-08-304303
2. Gong X, Gutala R, Jaiswal AK (2008) Quinone oxidoreductases and vitamin K metabolism. Vitam Horm 78:85-101. doi: 10.1016/S0083-6729(07)00005-2
3. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler 3rd ER, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney 3rd JA, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH, Investigators C (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369(24):2283-2293. doi: 10.1056/NEJMoa1310669
4. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstrom B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M, Group E-P (2013) A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 369(24):2294-2303. doi: 10.1056/NEJMoa1311386
5. Johnson JA, Cavallari LH (2015) Warfarin pharmacogenetics. Trends Cardiovasc Med 25(1):33-41. doi: 10.1016/j.tcm.2014.09.001
6. Lee KE, Chang BC, Kim HO, Yoon IK, Lee NR, Park HY, Gwak HS (2012) Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Ther Drug Monit 34(3):275-282. doi: 10.1097/FTD.0b013e318256a77c
7. Sun Y, Wu Z, Li S, Qin X, Li T, Xie L, Deng Y, Chen J (2015) Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: a systematic review and meta-analysis. Thromb Res 135(4):739-747. doi: 10.1016/j.thromres.2015.01.029
8. Kamali X, Wulasihan M, Yang YC, Lu WH, Liu ZQ, He PY (2013) Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang. Lipids Health Dis 12:149. doi: 10.1186/1476-511X-12-149
9. Jeong E, Lee KE, Jeong H, Chang BC, Gwak HS (2015) Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. Pharmacogenomics J 15(1):33-37. doi: 10.1038/tpj.2014.36
10. Wallin R, Martin LF (1987) Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo. Biochem J 241(2):389-396
11. Wallin R (1989) Vitamin K-dependent carboxylation in the developing rat: evidence for a similar mechanism of action of warfarin in fetal and adult livers. Pediatr Res 26(4):370-376. doi: 10.1203/00006450-198910000-00017
12. Wallin R, Martin LF (1985) Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest 76(5):1879-1884. doi: 10.1172/JCI112182
13. Ross D, Siegel D (2004) NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol 382:115-144. doi: 10.1016/S0076-6879(04)82008-1
14. Ernster L, Lind C, Rase B (1972) A study of the DT-diaphorase activity of warfarin-resistant rats. Eur J Biochem FEBS 25(1):198-206
15. Shyu HY, Fong CS, Fu YP, Shieh JC, Yin JH, Chang CY, Wang HW, Cheng CW (2010) Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke. Clin Chim Acta Int J Clin Chem 411(11-12):840-845. doi: 10.1016/j.cca.2010.02.071
16. Kelsey KT, Ross D, Traver RD, Christiani DC, Zuo ZF, Spitz MR, Wang M, Xu X, Lee BK, Schwartz BS, Wiencke JK (1997) Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 76(7):852-854
17. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296(5576):2225-2229. doi: 10.1126/science.1069424
18. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH, American College of Chest P (2012) Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e576S-e600S. doi: 10.1378/chest.11-2305
19. Matsuyama K, Matsumoto M, Sugita T, Nishizawa J, Yoshida K, Tokuda Y, Matsuo T (2002) Anticoagulant therapy in Japanese patients with mechanical mitral valves. Circ J Off J Jpn Circ Soc 66(7):668-670
20. Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M (2014) Mechanisms of miRNA-mediated gene regulation from common downregulation to mRNA-specific upregulation. Int J Genomics 2014:970607. doi: 10.1155/2014/970607
21. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH (2012) Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics 13(16):1925-1935. doi: 10.2217/pgs.12.164
22. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7):2329-2333. doi: 10.1182/blood-2005-03-1108
23. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111(8):4106-4112. doi: 10.1182/blood-2007-11-122010
24. Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR (2012) Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One 7(8):e44064. doi: 10.1371/journal.pone.0044064
25. Zhong SL, Yu XY, Liu Y, Xu D, Mai LP, Tan HH, Lin QX, Yang M, Lin SG (2012) Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients. Pharmacogenet Genomics 22(3):176-182. doi: 10.1097/FPC.0b013e32834f45f9
26. Jin DY, Tie JK, Stafford DW (2007) The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines. Biochemistry 46(24):7279-7283. doi: 10.1021/bi700527j